Simplified Pulmonary Embolism Severity Index (sPESI)
The sPESI is a validated 6-parameter bedside risk stratification tool that reliably identifies low-risk pulmonary embolism patients (score = 0) with <1% 30-day mortality who are candidates for outpatient management, though it has not been prospectively tested to guide therapeutic decisions. 1
How sPESI is Calculated
The sPESI assigns 1 point for each of the following parameters present at presentation 1:
- Age >80 years
- Cancer (active malignancy)
- Chronic cardiopulmonary disease (heart failure or chronic lung disease)
- Heart rate ≥110 beats per minute
- Systolic blood pressure <100 mmHg
- Oxygen saturation <90%
Score interpretation:
- sPESI = 0: Low-risk (30-day mortality ~1.0-1.1%)
- sPESI ≥1: Higher-risk (30-day mortality ~8.9-10.9%)
Clinical Utility and Management Implications
Risk Stratification Framework
The primary strength of sPESI lies in identifying low-risk patients suitable for home treatment or early discharge 1. The 2019 ESC Guidelines incorporate sPESI into their risk classification system where low-risk PE is defined by hemodynamic stability AND negative sPESI (or PESI class I-II) 1.
Disposition Decisions
Patients with sPESI = 0 are appropriate candidates for outpatient management, particularly when treated with direct oral anticoagulants (DOACs) like apixaban or rivaroxaban that don't require initial heparin bridging 2. However, real-world data shows only 17% of eligible low-risk patients are actually treated at home, indicating significant underutilization 3.
Additional factors that should discourage outpatient treatment even with sPESI = 0:
- Right ventricular dysfunction on imaging
- Elevated cardiac biomarkers (troponin, BNP/NT-proBNP)
- Concomitant deep vein thrombosis
- Lack of adequate home support or follow-up 1, 2
Important Caveats
The sPESI was designed for 30-day mortality prediction and performs less well for longer-term outcomes 4, 5. Discrimination decreases over time (AUC 0.727 at 30 days vs 0.665 at 1 year) 5.
The sPESI misclassifies approximately 15% of patients as higher-risk who actually have low mortality (<1%), potentially leading to unnecessary hospitalizations 6. This occurs because sPESI is more conservative than the original PESI, identifying fewer patients as low-risk (27.5% vs 41.0%) 6.
Recent evidence suggests the heart rate threshold of ≥110 bpm may be suboptimal - lowering to ≥100 bpm improves discrimination and event detection while maintaining clinical practicality 7.
Comparison to Original PESI
The sPESI was developed to simplify the complex 11-variable original PESI that uses differential weighting 1, 8. Both scores have similar prognostic accuracy (AUC ~0.75) and negative predictive values (>98%), but sPESI is far easier to calculate at the bedside 8, 9. The original PESI identifies more patients as low-risk but requires more complex calculation 6.
Integration with Other Risk Markers
For intermediate-risk PE patients (hemodynamically stable but sPESI ≥1), further stratification requires imaging for RV dysfunction and cardiac biomarkers 1. The combination of RV dysfunction on echocardiogram/CTPA plus positive troponin is the only risk stratification approach prospectively tested in randomized trials to guide reperfusion therapy decisions 1.
Adding RV dysfunction assessment to sPESI modestly improves discrimination, particularly when using lower heart rate thresholds (≥80-100 bpm), achieving >99% negative predictive value 7.